CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) Director Leonard Post sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $54.50, for a total value of $54,500.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at approximately $54,500. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
CG Oncology Stock Performance
CG Oncology stock opened at $53.72 on Monday. The stock has a market cap of $4.74 billion, a P/E ratio of -23.06 and a beta of 0.31. The stock has a 50 day moving average of $65.98 and a 200-day moving average of $56.13. CG Oncology, Inc. has a 52 week low of $23.65 and a 52 week high of $75.50.
CG Oncology (NASDAQ:CGON – Get Free Report) last released its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, equities analysts predict that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Analysis on CG Oncology
Institutional Investors Weigh In On CG Oncology
Large investors have recently added to or reduced their stakes in the stock. Candriam S.C.A. increased its position in CG Oncology by 35.9% in the third quarter. Candriam S.C.A. now owns 1,037,892 shares of the company’s stock worth $41,806,000 after buying an additional 274,312 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of CG Oncology by 321.3% during the third quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock valued at $9,179,000 after purchasing an additional 173,785 shares during the period. Vanguard Group Inc. increased its holdings in shares of CG Oncology by 11.4% during the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after purchasing an additional 670,770 shares during the period. Mangrove Partners IM LLC increased its holdings in shares of CG Oncology by 21.0% during the third quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock valued at $27,056,000 after purchasing an additional 116,575 shares during the period. Finally, Sivik Global Healthcare LLC acquired a new position in shares of CG Oncology during the fourth quarter valued at $1,453,000. 26.56% of the stock is owned by institutional investors and hedge funds.
CG Oncology Company Profile
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Featured Stories
- Five stocks we like better than CG Oncology
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
